Cardlytics, Inc. (NASDAQ:CDLX) Receives Consensus Rating of “Hold” from Brokerages

Cardlytics, Inc. (NASDAQ:CDLXGet Free Report) has earned a consensus recommendation of “Hold” from the seven analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $6.92.

CDLX has been the subject of a number of research analyst reports. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Friday, January 17th. Finally, Evercore ISI initiated coverage on Cardlytics in a research report on Friday, October 11th. They issued an “in-line” rating and a $4.00 price objective on the stock.

Check Out Our Latest Research Report on Cardlytics

Insiders Place Their Bets

In related news, CFO Alexis Desieno sold 8,854 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total value of $32,494.18. Following the sale, the chief financial officer now directly owns 121,976 shares in the company, valued at $447,651.92. This trade represents a 6.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Amit Gupta sold 15,160 shares of Cardlytics stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $3.92, for a total transaction of $59,427.20. Following the transaction, the chief executive officer now directly owns 215,494 shares in the company, valued at $844,736.48. The trade was a 6.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,560 shares of company stock valued at $223,687. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP raised its stake in Cardlytics by 1,273.2% during the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after buying an additional 354,474 shares during the period. RBF Capital LLC lifted its holdings in shares of Cardlytics by 311.9% during the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Cardlytics by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after purchasing an additional 73,484 shares during the period. Barclays PLC increased its stake in Cardlytics by 223.9% during the 3rd quarter. Barclays PLC now owns 58,026 shares of the company’s stock worth $186,000 after purchasing an additional 40,112 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Cardlytics during the 3rd quarter worth approximately $45,000. 68.10% of the stock is owned by institutional investors.

Cardlytics Stock Down 8.1 %

NASDAQ CDLX opened at $3.16 on Thursday. The stock’s 50 day simple moving average is $3.65 and its 200 day simple moving average is $4.27. Cardlytics has a one year low of $2.76 and a one year high of $20.52. The firm has a market cap of $160.60 million, a PE ratio of -0.52 and a beta of 1.53. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18.

Cardlytics (NASDAQ:CDLXGet Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. During the same quarter in the prior year, the business earned ($0.26) earnings per share. The business’s revenue for the quarter was down 15.1% on a year-over-year basis. As a group, sell-side analysts forecast that Cardlytics will post -1.52 earnings per share for the current fiscal year.

Cardlytics Company Profile

(Get Free Report

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

See Also

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.